id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1257730,fca0d781-a28d-4d9c-9b57-72ee165a99ad,Q2,"CYBER SECURITY RESEARCH CONSULTANTS, LLC",91694,PDFRAZER CONSULTING INC CANADIAN INTERNATIONAL PHARMACY ASSOCIATION,2012,second_quarter,PHA,"Food and Drug Safety Globalization Act
Monitoring Dorgan-Snowe Drug reimportation from Canada
Monitoring Protect IP ACT, Monitoring SOPA
Monitoring FDA Reauthorization Act","HOUSE OF REPRESENTATIVES,SENATE",21000,,0,0,2012-07-02T15:00:11.417000-04:00
1258009,3a18555e-1bc0-4e6a-bb51-f1d63e0668f6,Q2,"SHELTER ROCK STRATEGIES, LLC",400772326,NEW YORK MEDICAL COLLEGE,2012,second_quarter,PHA,"BARDA Solicitation HHS 11-100SOL-00011, Centers for Innovation in Advanced Development and Manufacturing, Assess the likelihood this solicitation will get funded, assess competition, assist in writing and getting signed memoranda of support from the NY Congressional Delegation, and assist in obtaining support from NY State to aid the client's proposal.","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2012-07-03T13:38:10.217000-04:00
1258098,d38dbbed-253f-4ab8-a41a-f0a1eb5e397c,Q2,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2012,second_quarter,PHA,"Increased appropriations for systems to shorten the time between development of a drug and its release to the public
FDA reform as it relates to drug development and research         FDA User Fee Bill
Collaborative research on drug development                                 anti-malarial pharmaceuticals
FY 2011 Agricultural Appropriations                                             human factors research related to neuropharmaceuticals","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,State, Dept of (DOS),Transportation, Dept of (DOT)",,88684,0,0,2012-07-03T16:59:14.913000-04:00
1258189,90b07013-6ce7-43d9-963f-c9fbd26729ce,Q2,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2012,second_quarter,PHA,"H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which creates and antitrust exemption for certain pharmacies.

Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy. Issues impacting PBMs included in the Prescription Drug User Fee Act reauthorization and the Generic Drug User Fee Reauthorization","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-05T11:09:34.033000-04:00
1258193,616bb44d-53f1-45e5-a190-e34c2c1a14be,2A,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2012,second_quarter,PHA,"H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which creates and antitrust exemption for certain pharmacies.

Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy. Issues impacting PBMs included in the Prescription Drug User Fee Act reauthorization and the Generic Drug User Fee Reauthorization","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2012-07-05T11:10:35.127000-04:00
1258262,43d896e7-6a56-48af-a92d-b79c33545364,Q2,INJURED WORKERS PHARMACY,400765309,INJURED WORKERS PHARMACY,2012,second_quarter,PHA,Transparency of Pharmacy Benefit Managers (bill sponsored by Rep. McMorris-Rodgers and Senator Mark Pryor); Longshore and Harbor Workers Amendment Act of 2011 sponsored by Senator Isakson.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2012-07-05T13:49:07.670000-04:00
1258375,8d8da5a7-ba19-4f0b-8d4d-e341a6483704,Q2,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2012,second_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,61700,0,0,2012-07-05T15:08:09.390000-04:00
1258607,1417d12b-9115-4cac-9d6e-5aa8c779b0e1,Q2,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2012,second_quarter,PHA,"H.R. 1946 - Preserving Our Hometown Independent Pharmacies Act of 2011, which allows for an antitrust exception for certain pharmacies.

Issues related to the practice of giving coupons for certain prescription medications. S. 3187 - FDA Safety and Innovation Act - Issues related to supply chain safety, treatment of controlled substances and REMS policies.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2012-07-06T14:03:01.527000-04:00
1258659,ab80f880-f4d9-48a8-829a-c763c4b4a4db,Q2,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2012,second_quarter,PHA,"H.R. 2182/S. 1734 - Generating Antibiotic Incentives Now Act .  Supporting work to increase innovation and development of new antibiotics.
S. 1584 - Drug Safety and Accountability Act- Supporting legislation and related Congressional activity regarding upstream supply stream safety. H.R. 3026- Safeguarding America's Pharmaceuticals Act. Supporting legislation and congressional activity regarding downstream supply chain safety.

S. 3187 - The FDA Safety and Innovation Act- specific work on antibiotic innovation, up and down stream supply chain issues, and medical device policies.

Policies related to the growing concerns regarding drug shortage issues in hospitals across the country.

Related issues being considered in pending User Fee Reauthorization legislation.","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-06T16:44:43.090000-04:00
1258693,b8fe620c-082b-4c04-b79c-421d934e2189,Q2,AMERICAN AMBULANCE ASSOCIATION,56018,AMERICAN AMBULANCE ASSOCIATION,2012,second_quarter,PHA,Supported efforts to address the drug shortage issue in the Food and Drug Administration Safety and Innovation Act (S. 3187) as it pertains to emergency medical service providers.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",,240000,0,0,2012-07-07T09:30:24.563000-04:00
1258778,028d0ba1-1b5b-43b8-9535-af9eefa30032,Q2,"NAHIGIAN STRATEGIES, LLC",322897,TEVA PHARMACEUTICALS USA INC,2012,second_quarter,PHA,Generic pharmaceutical issues.  Advocated for provisions related to the FDA user fee legislation.,,30000,,0,0,2012-07-09T08:33:58.870000-04:00
1259277,6a7dc566-4717-462a-9219-16ee1bacb056,Q2,LONG TERM CARE PHARMACY ALLIANCE,400309443,LONG TERM CARE PHARMACY ALLIANCE,2012,second_quarter,PHA,Medicare Part D,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,201000,0,0,2012-07-09T14:44:06.780000-04:00
1259835,46aa986f-d9bf-4195-a22e-6b1574e7feb2,Q2,HOLLAND & KNIGHT LLP,18466,"SAFECOR HEALTH, LLC",2012,second_quarter,PHA,"Drug supply chain provisions in federal legislation; specifically S.3187, The Food & Drug Administration Safety & Innovation Act and H.R. 5651, The Food & Drug Administration Reform Act of 2012. Advocated for provisions recognizing the role of drug repackagers and against provisions to make certain hydrocodone products schedule 2 controlled substances.","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2012-07-10T15:12:28.827000-04:00
1260608,fa9e8e30-db77-442a-ba18-a2c8d567ef1f,Q2,"HEARTLAND SOLUTIONS GROUP, INC.",312133,ZEBRA TECHNOLOGIES CORPORATION,2012,second_quarter,PHA,"Any and all issues related to barcode, secure identification and real-time location systems.","HOUSE OF REPRESENTATIVES,SENATE",41250,,0,0,2012-07-11T15:55:50.380000-04:00
1260624,006f3c9b-d270-450d-9dc9-8f2b64e1c919,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"POZEN, INC.",2012,second_quarter,PHA,To provide incentives for new drug development.  No specific bills pending.,"HOUSE OF REPRESENTATIVES,SENATE",36000,,0,0,2012-07-11T16:01:58.143000-04:00
1260631,c4e8038c-27ea-47f9-99d7-76bd09df9dad,Q2,"THE OB-C GROUP, LLC",29802,ELI LILLY,2012,second_quarter,PHA,No specific bill number: matters relating to pharmaceutical manufacturers and Medicare Part D.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2012-07-11T16:07:03.750000-04:00
1260653,bdd45747-b59c-495d-8596-8f713efb7291,Q2,DENNY MILLER ASSOCIATES,25328,CELL THERAPEUTICS,2012,second_quarter,PHA,"S. 3187, Food and Drug Administration Safety and Innovation Act of 2012, provisions relating to the approval of new drugs.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-11T16:22:16.397000-04:00
1260704,a40a0370-b69b-43f7-9958-90d77142b90c,Q2,"DUTKO WORLDWIDE, LLC",12868,NEWAYS INTERNATIONAL,2012,second_quarter,PHA,"Monitor legislation pertaining to dietary supplements and pharmaceuticals, particularly the Food Safety Modernization Act (PL 111-353) and Patient Protection and Affordable Care Act (PL 111-148).","Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2012-07-11T17:34:49.167000-04:00
1260860,f87f2484-6678-45f8-8c02-9b62094936a9,Q2,"TAUZIN CONSULTANTS, LLC",400671007,"RESILIENT NETWORK SYSTEMS, INC.",2012,second_quarter,PHA,"Cross-agency collaboration and information sharing for R&D, clinical trials, and recruitment","Director of National Intelligence (ODNI),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2012-07-12T09:59:11-04:00
1261005,464adfd4-5853-4be0-9236-3e2889feaaa8,Q2,ASSOCIATION FOR ACCESSIBLE MEDICINES,16032,ASSOCIATION FOR ACCESSIBLE MEDICINES,2012,second_quarter,PHA,"FY 2013 Budget, Implementation of Health Care Reform, Implementation of Generic Biologics, Prescription Drug Safety, Counterfeit Drugs/Import Safety/Pedigree, Prescription Drug Shortages, Authorized Generics, Prescription Drug Importation/Re-Importation, drug shortages, prescription drug abuse and generic drugs H.R.2182  Generating Antibiotic Incentives Now Act of 2011
H.R.3026 - Safeguarding America's Pharmaceuticals Act of 2011 
H.R.3839 - Drug Shortage Prevention Act of 2012
H.R.3988 - Generic Drug and Biosimilar User Fee Act of 2012
H.R.3995 - Protecting Consumer Access to Generic Drugs Act of 2012
H.R.4332 - Generic Drug Application Review Fairness Act of 2012
H.R. 5651 - Food and Drug Administration Reform Act of 2012
S.44  Medicare Prescription Drug Negotiation Act
S.296 and H.R.2245  Preserving Access to Life-Saving Medication Act
S.373  Fair Prescription Drug Competition Act
S.1584 - Drug Safety and Accountability Act of 2011
S.1734 - Generating Antibiotic Incentives Now Act of 2011
S.2295 - Patient Safety and Generic Labeling Improvement Act
S.2516 - Food and Drug Administration Safety and Innovation Act
S.3187  Food and Drug Administration Safety and Innovation Act","Centers For Medicare and Medicaid Services (CMS),Commerce, Dept of (DOC),Congressional Budget Office (CBO),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Office of Management & Budget (OMB),Patent & Trademark Office (PTO),SENATE,U.S. Trade Representative (USTR),White House Office",,504925,0,0,2012-07-12T11:52:01.590000-04:00
1261185,96d9daaa-f721-4b4c-9af9-38d6f3ac7517,Q2,NEW JERSEY HOSPITAL ASSOCIATION,29128,NEW JERSEY HOSPITAL ASSOCIATION,2012,second_quarter,PHA,"Support S. 3187, the Food and Drug Administration Safety and Innovation Act, which included industry supported provisions to help alleviate critical drug shortages.","HOUSE OF REPRESENTATIVES,SENATE",,70000,0,0,2012-07-12T15:18:37.647000-04:00
1261193,19911757-0d23-4ae0-a69d-ab6eac8987e4,Q2,AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS,1672,AMERICAN ASSOCIATION OF ORAL AND MAXILLOFACIAL SURGEONS,2012,second_quarter,PHA,"the Prescription Drug Abuse Prevention and Treatment Act of 2011 (S. 507/H.R. 1925)
the Stop Oxy Abuse Act of 2011 (H.R. 1316)
the Ryan Creedon Act of 2011 (H.R. 2119)
Prescription Drug User Fee Act (PDUFA) reauthorization legislation (H.R. 5651/S. 3187)","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE",,117767,0,0,2012-07-12T15:22:41.100000-04:00
1261217,48bf2391-07a1-4c00-884d-e0bc0603f138,Q2,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2012,second_quarter,PHA,"CMS Average Manufacturer Price (AMP) Final Rule. Reporting by manufacturers and calculation.
Potential prescription drug track-and-trace legislation. RxTEC
National Average Drug Acuisition Cost (NADAC) implementation. Calculation and Process","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2012-07-12T15:51:49.337000-04:00
1261291,e2fa8db2-aa81-42ad-9ace-ec874e6285b7,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"BRAIDWOOD MANAGEMENT, INC.",2012,second_quarter,PHA,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.  No specific legislation has been introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.   No specific legislation has been introduced yet.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-07-12T16:58:31.483000-04:00
1261300,ef702ed0-4326-44a6-aabd-1688e8451258,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,DIAMONDBACK DRUGS,2012,second_quarter,PHA,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.   No specific legislation has been introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.","HOUSE OF REPRESENTATIVES,SENATE",6000,,0,0,2012-07-12T17:05:35.747000-04:00
1261349,bbf34b52-4b5b-4173-a16b-68ba45116eb9,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"VETERINARY PHARMACIES OF AMERICA, INC.",2012,second_quarter,PHA,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.  No specific legislation introduced yet.
Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation introduced yet.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-07-12T17:25:57.753000-04:00
1261380,347c89ec-f95a-41a1-a32d-649aa6766f94,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WEDGEWOOD VILLAGE PHARMACY, INC.",2012,second_quarter,PHA,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.   No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation has been introduced yet.

Regulatory issues involving compounded 17P and compounded Avastin.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-07-12T17:33:07.937000-04:00
1261391,52b94dbf-16a3-4867-840f-7092121257d9,Q2,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"WOMEN'S INTERNATIONAL PHARMACY, INC.",2012,second_quarter,PHA,"Issues related to the compounding pharmacies, in particular relating to FDA action to ban the hormone estriol from compounded estrogens.  No specific legislation introduced yet. Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation introduced yet.

Regulatory issues involving compounded 17P.","HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2012-07-12T17:41:15.013000-04:00
1261398,794f0916-a7b8-4184-8b0f-54add4ed88ac,Q2,CAPITOL HILL CONSULTING GROUP,72053,PURDUE PHARMA LLP,2012,second_quarter,PHA,"Controlled Drug Substances Act (21 USC 13)
Stop Oxy Abuse Act (H.R. 1316)","HOUSE OF REPRESENTATIVES,SENATE",32000,,0,0,2012-07-12T17:44:17.667000-04:00
1261490,dbd716d0-cfac-4f01-882c-77b3b328754e,Q2,"GREENBERG TRAURIG, LLP",16896,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION (NCPA),2012,second_quarter,PHA,Health care legislative and regulatory issues affecting independent community pharmacies.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB)",30000,,0,0,2012-07-13T07:21:24.173000-04:00
1261551,64548c82-fb2f-4cc0-a480-b3629f6e4a03,Q2,APOTEX CORP.,310973,APOTEX CORP.,2012,second_quarter,PHA,"S. 1882, The Fair and Immediate Release of Generics Act
S. 27, the Preserve Access to Affordable Pharmaceuticals Act
HR 4332, the Generic Drug Application Review Fairness Act Amending Section 505(j) of the Food, Drug and Cosmetic Act, concerning the ability of generic pharmaceutical manufacturers to file counterclaims seeking the correction of incorrect patent information submitted to FDA's Orange Book by patent owners of New Drug Applications

Supreme Court consideration of Novo Nordisk A/S and Novo Nordisk Inc. vs Caraco Pharmaceutical Laboratories Ltd. and Sun Pharmacuetical Industries Ltd.

S. 2516, the Food and Drug Innovation and Safety Act:
    Title VIII, Generating Antibiotic Incentives,
    Title XI, Other Provisions, Section 1131, Drug Development and Testing 

HR 5651. the Food and Drug Administration Reform Act:
    Title VIII, Drug Regulatory Improvements, Subtitle F, Miscellaneous, Section 862, Extension of period for first applicant to         
    obtain tentative approval without forfeiting 180-day exclusivity period, Section 863, Final agency action relating to petitions
    and civil actions

S. 3187.PCS/.ES, the Food and Drug Administration Safety and Innovation Act:
    Title XI, Other Provisions,  Subtitle C, Miscellaneous Provisions, Section 1131, Drug Development and Testing

S AMDT 2111 to S. 3187, concerning pharmaceutical market blockages caused by parked 180 day exclusivity periods 

S. 3187.EAH, the Food and Drug Administration Safety and Innovation Act:
    Title XI, Other Provisions, Subtitle C, Miscellaneous Provisiosn, Section 1133, Extension of period for first applicant to    
    obtain tentative approval without forfeiting 180 day exclusivity period, Section 1135, Final agency action related to petitions   
    and civil actions 

Establishment of a federal track and trace system for pharmaceuticals","Congressional Budget Office (CBO),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE",,170000,0,0,2012-07-13T09:41:12.413000-04:00
1261670,42b19de4-efe1-468d-91d9-0a4af379fd65,Q2,WINSTON & STRAWN LLP,41682,FRESENIUS KABI USA (FORMERLY KNOWN AS APP PHARMACEUTICALS INC ),2012,second_quarter,PHA,"Represent the client on issues related to assuring a safe, reliable supply of heparin and also on patent matters, including settlements and extensions.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2012-07-13T10:48:55.073000-04:00
1261813,35696117-910e-45d2-ab68-9ed02e21d959,Q2,"NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC",400689052,TEVA PHARMACUETICALS USA,2012,second_quarter,PHA,PDUFA and user fees issues,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-13T11:42:00.677000-04:00
1261841,a599942f-07d9-409e-8c48-f99794bf228b,Q2,"NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC",400689052,WOCKHARDT USA LLC,2012,second_quarter,PHA,Issues in PDUFA; preemption under FDA Act,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-13T11:52:16.733000-04:00
1262597,55299366-0083-466e-b8f7-7f62825590e4,Q2,BAKER DONELSON BEARMAN CALDWELL & BERKOWITZ,5153,THE MEDICINES COMPANY,2012,second_quarter,PHA,Regulatory and Reimbursement,"Defense, Dept of (DOD),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2012-07-13T19:19:17.040000-04:00
1263473,296b5ec1-0dac-4d80-983e-bded5afb8e65,Q2,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,11003,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,2012,second_quarter,PHA,"H.R. 5651, legislation that would reauthorize and modify the Food and Drug Administrations (FDA) prescription drug and medical device user-fee programs; all sections","HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2012-07-16T08:17:40.327000-04:00
1264028,09867d49-61cf-4ce5-99e4-7bc98463e2a6,Q2,GRIZZLE COMPANY,16987,KENTUCKYONE HEALTH (FORMERLY JEWISH HOSPITAL HEALTH CARE SERVICES),2012,second_quarter,PHA,"S.3187, The Food and Drug Administration Safety and Innovation Act (FDASIA): Support provision to give FDA enhanced authority to address drug shortages.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2012-07-16T13:02:49.467000-04:00
1264373,066281c1-74b3-46a9-82e7-e9da961a5b10,Q2,EVERTZ GROUP LLC,400497446,MYLAN INC.,2012,second_quarter,PHA,Involvement of the generic pharmaceutical industry in the President's Emergency Plan for AIDS Relief (PEPFAR). Supply Chain Management System of the PEPFAR program.,"Office of Natl AIDS Policy,SENATE,State, Dept of (DOS),U.S. Agency for International Development (USAID)",30000,,0,0,2012-07-16T15:00:38.377000-04:00
1264634,09551281-9865-4860-811d-9d53555da353,Q2,STEVE BUYER GROUP,400701097,OMNICARE,2012,second_quarter,PHA,Advocacy in support of S 1560 promoting changes to the Controlled Substance Act providing access to pain medication for nursing.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2012-07-16T16:06:04.020000-04:00
1264749,93ead602-b34d-416f-9d98-8723c2035f98,Q2,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,3457,AMERICAN SOCIETY OF HEALTH-SYSTEM PHARMACISTS,2012,second_quarter,PHA,"S. 3187, H.R. 5651, Support for the Drug Shortages provisions within the ""Food and Drug Administration Safety and Innovation Act.""  Contact concerning Food and Drug Administration (FDA) authority to manage drug shortages.  Communications to FDA on approval of biosimilars, drug safety, expansion of over the counter (OTC) medicines.  Communications to Health Resources and Services Administration on 340B drug discount program.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,250000,0,0,2012-07-16T16:37:00.713000-04:00
1264821,7ce30cde-4670-4055-b9c3-f12f89394f7b,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2012,second_quarter,PHA,Issues related to anti-epileptic drugs.,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",5000,,0,0,2012-07-16T16:46:36.520000-04:00
1264861,fb172deb-3185-4363-8eb0-675d68616c1e,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2012,second_quarter,PHA,"Issues related to drug shortages. S.296/HR2245 Preserving Access to Life Saving Medications Act, HR3839 Drug Shortage Prevention Act; S.3187, FDA Safety and Innovation Act.","Centers For Disease Control & Prevention (CDC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2012-07-16T16:55:51.250000-04:00
1264888,2fe1967b-9f42-46b5-9c0c-65b2776de717,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2012,second_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program. S.3187, FDA Safety and Innovation Act.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",50000,,0,0,2012-07-16T17:00:00.737000-04:00
1264898,68b3ec4a-79da-4c60-b969-667475df10d6,Q2,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2012,second_quarter,PHA,Issues realted to the 340B drug discount program.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2012-07-16T17:06:06.330000-04:00
1265012,1fde7ce9-244b-49b6-af75-b2d7f5654044,Q2,MCDERMOTT WILL & SCHULTE LLP,24338,ISIS PHARMACEUTICALS,2012,second_quarter,PHA,"Promote policies and legislation that foster medical research and development, as well as the antisense drug technology which promises relief from potential diseases including cancer, AIDs and diabetes.  Specifically, work on patent reform legislation, including S. 23 and H.R. 1249.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2012-07-16T17:35:55.847000-04:00
1265408,63e869a8-390e-4000-a39a-7f06945aff1b,Q2,"EXPRESS SCRIPTS, INC.",294416,"EXPRESS SCRIPTS, INC.",2012,second_quarter,PHA,"Policies related to the Federal Employees Health Benefit Program's pharmacy benefit (HR 979); Regulatory design and coverage of pharmacy benefits in health reform Exchanges and the commercial market (EHB, grandfathering, Rx quality, eRx, PBM disclosure requirements, MLR); legislation to promote generic drugs (S. 27); regulatory implementation of a pathway for the approval of biosimilars; REMs; 340b program; legislation placing restrictions on pharmacy benefit design (HR 1971, S 1058). FDA Safety and Innovation Act:  S. 3187, H.R.3988, H.R.4087, H.R.5334, S.2236, S.2289, S.2516:  issues regarding making prescription drugs more affordable (generic user fees; pedigree; pathway for biosimilars; REMs).","Centers For Medicare and Medicaid Services (CMS),Congressional Budget Office (CBO),Executive Office of the President (EOP),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),SENATE,White House Office",,470000,0,0,2012-07-17T09:41:51.390000-04:00
1265430,29734739-0bdc-401a-9a68-93f4ef555fd2,Q2,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,3446,AMERICAN SOCIETY OF CONSULTANT PHARMACISTS,2012,second_quarter,PHA,Prescribing and Dispensing of Controlled Substances under the Controlled Substances Act; Health IT; Pharmacy Student Loan Repayment; Medication Use in Long-Term Care,"Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2012-07-17T09:54:57.600000-04:00
1265479,9124828c-6b9f-4c26-a8d1-a0807aeb01a3,Q2,HARLOW GOVERNMENT RELATIONS LLC,400745232,AMERICAN MEDICAL ASSOCIATION,2012,second_quarter,PHA,online pharmacy regulation/registration,"HOUSE OF REPRESENTATIVES,SENATE",67500,,0,0,2012-07-17T10:06:29.500000-04:00
1266274,758b9c7d-3956-4012-8ca3-48445fcbea28,Q2,MCDERMOTT WILL & SCHULTE LLP,24338,"ALLERGAN, INC.",2012,second_quarter,PHA,Issues related to Section 340B of the Public Health Service Act; FDA issues; health reform implementation,"Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2012-07-17T13:26:47.187000-04:00
1266561,dea865cf-35d4-4bcf-a3f8-98acb2d3db3b,Q2,MCDERMOTT WILL & SCHULTE LLP,24338,RURAL REFERRAL CENTER/SOLE COMMUNITY HOSPITAL COALITION,2012,second_quarter,PHA,Amendments to Section 340B of the Public Health Service Act to gain eligibility for rural referral centers and sole community hospitals in the federal discount drug purchasing program.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",200000,,0,0,2012-07-17T14:31:28.360000-04:00
1266620,9b0b8931-6c72-4649-af02-4409ba2a69cd,Q2,RICCHETTI INCORPORATED,62778,ELI LILLY AND COMPANY,2012,second_quarter,PHA,"issues related to pediatric exclusivity policy
issues related to PDUFA reauthorization","HOUSE OF REPRESENTATIVES,SENATE",15000,,0,0,2012-07-17T14:44:23.143000-04:00
1266685,11bdf878-3b0c-4777-985f-123ba8f91412,Q2,RICCHETTI INCORPORATED,62778,SANOFI-AVENTIS U S INC,2012,second_quarter,PHA,issues relating to PDUFA reauthorization,"HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)",30000,,0,0,2012-07-17T15:04:29.033000-04:00
1266910,3d5b0aa3-0c23-46c2-adda-8ffe1f618d86,Q2,AMERICAN ACADEMY OF FAMILY PHYSICIANS,1342,AMERICAN ACADEMY OF FAMILY PHYSICIANS,2012,second_quarter,PHA,"No Bill Number, Proposal to create ""Special medical use"" category of prescription drugs, Should FDA create category of drugs that non physicians like pharmacists could prescribe.
No Bill Number, National Priorities and Research Agenda, PCORI should focus research on more common medical conditions first.","Agency for Healthcare Research & Quality (AHRQ),Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),SENATE,White House Office",,767597,0,0,2012-07-17T15:48:09.030000-04:00
1266935,02d5deb7-3886-426a-8880-562449a5733d,Q2,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2012,second_quarter,PHA,"P.L. 111-148, Patient Protection and Affordable Care Act of 2009 (ACA) and P.L. 111-152, The Health Care & Education Affordability Reconciliation Act of 2010: Issues regarding comparative effectiveness, implementation of Physician Payment Sunshine provisions and Prescription Drug Sample reporting provisions;  S.3187 FDA Safety and Innovation Act (PDUFA V); H.R. 4274 Best Pharmaceuticals for Children Act/Pediatric Research Exclusivity Act; H.R. 3026 Safeguarding America's Pharmaceuticals Act of 2011; Pharmaceutical Traceability Enhancement Code (Rx TEC) Act; H.R. 5973 FY2013 Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act (FDA funding); 340B","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Natl Institutes of Health (NIH),SENATE,White House Office",,900000,0,0,2012-07-17T15:55:24.767000-04:00
1266950,479d3dcc-61bc-44fc-87c1-20072bb63d33,Q2,THE HOSPITAL & HEALTHSYSTEM ASSOCIATION OF PENNSYLVANIA,18672,HOSPITAL & HEALTHSYSTEM ASSOCIATION OF PENNSYLVANIA,2012,second_quarter,PHA,"H.R. 5651, Food and Drug Administration Reform Act of 2012
S.3187, Food and Drug Administration Safety and Innovation Act","HOUSE OF REPRESENTATIVES,SENATE",,100000,0,0,2012-07-17T15:56:29.047000-04:00
1267068,7afd5a90-2378-486b-b1c9-9687ed1de9a8,Q2,VENABLE LLP,39941,ENDO PHARMACEUTICALS INC,2012,second_quarter,PHA,"General issues affecting the pharmaceutical industry and bioequivelence.  (Generic pharmaceutical user fee act; H.R. 5651.)
The Life Sciences Investment Act (S. 1410; H.R. 2632)","HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2012-07-17T16:14:17.010000-04:00
1267396,95751c7b-7534-4a29-84cd-48d8f27f0c04,Q2,"WHITMER & WORRALL, LLC",292892,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2012,second_quarter,PHA,Issues related to monitoring healthcare reform.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-17T17:01:50.593000-04:00
1267638,fe8197fb-12e7-471d-9825-b7339bc08a2f,Q2,SQUIRE PATTON BOGGS,30906,KV PHARMACEUTICAL COMPANY,2012,second_quarter,PHA,Issues regarding Medicaid coverage of Makena and regulatory treatment of Makena.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2012-07-17T18:00:42.823000-04:00
1267789,ce747526-546f-4ade-a9d8-2d73eea857da,Q2,SQUIRE PATTON BOGGS,30906,RANBAXY INC.,2012,second_quarter,PHA,"S. 27, Preserve Access to Affordable Generics; H.R. 1483, Drug Safety Enhancement Act; Implementation of P.L. 111-148, Patient Protection & Affordable Care Act; Prescription Drug User Fee Reauthorization issues.","HOUSE OF REPRESENTATIVES,SENATE",180000,,0,0,2012-07-17T18:36:00.367000-04:00
1267998,f43530a9-5181-4df2-910e-b128b8ec9cfe,Q2,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2012,second_quarter,PHA,"Importation of Prescription Drugs (S. 319, H.R. 147); Rx Pedigree (H.R. 3026/S. 3187); NASPER Reauthorization (H.R. 866); Presecription Drug Monitoring Programs (S. 2254/H.R. 4292/S. 3187); Pill Mill Crackdown Act (H.R. 1065/S. 1760/S. 2297); Drug Abuse (S. 507); Drug Shortages (S. 296/ H.R. 2245/H.R. 3839/S. 3187/H.R. 5853/H.R. 5651); Cargo/Product Theft 
(S.1002/H.R. 4223); Import Safety(S.1584); Counterfeit Drugs(S.1886/H.R. 3668/S.3187); Internet Pharmacy(S.2002/H.R. 4095)","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,323000,0,0,2012-07-18T08:58:02.590000-04:00
1268039,cbdb8eb4-78f5-482b-aa9b-9f689754149f,2T,POLICY DIRECTIONS INC.,31747,ALPHARMA INC/PFIZER ANIMAL HEALTH (FORMERLY KNOWN AS ALPHARMA INC ),2012,second_quarter,PHA,"Antibiotics in animal foods
Drug approvals
Drugs in animal foods Implementation of: All titles, to end the use of certain antibiotics in animal feed if those antibiotics are used in human medicine.

HR 965 and S. 1211 and efforts to require the manufacturers of antibiotics used in animal feed to make certain reports to FDA.

Legislation to reform FDA regulation of federal imported and domestic food safety with emphasis on those titles related to the import of ingredients for food and drugs, as well as country-of-origin labeling.

Monitor legislative and regulatory developments related to the Animal Drug User Fee Act reauthorization, with related developments of the Generic Animal Drug UserFee Act.

Monitor developments of the Food & Drug Administrations development of its Advanced Feed Safety System related to the use of animal drugs in livestock and poultry feeds.","Agriculture, Dept of (USDA),Energy, Dept of,Environmental Protection Agency (EPA),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",20000,,0,1,2012-07-18T09:21:22.747000-04:00
1268212,f7c9c44c-09e9-4760-9829-ac3ffe6d4bad,Q2,"OMNICARE, INC.",321112,OMNICARE INC,2012,second_quarter,PHA,Antipsychotic drug use in nursing homes,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,140000,0,0,2012-07-18T09:58:43.037000-04:00
1268535,21ebd700-4467-4f7b-bb9d-36fd593da921,Q2,BROWN RUDNICK LLP,287895,HEALTHCARE DISTRIBUTION ALLIANCE F/K/A HEALTHCARE DISTRIBUTION MANAGEMENT ASSOC,2012,second_quarter,PHA,Issues related to supply chain safety; H.R. 3026 Safeguarding America's Pharmaceuticals Act of 2011; H.R. 147 & S. 319 Pharmaceutical Market Access and Drug Safety Act; H.R. 866 - National All Schedules Prescription Reporting Reauthorization Act of 2011; H.R. 1065 & S. 1760- Pill Mill Crackdown Act of 2011; H.R. 5651 & S. 2516 & S.3187 to drug shortages,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2012-07-18T10:55:20.507000-04:00
1268782,0f829e04-d294-4c04-8970-26600f242a31,Q2,"CARPI & CLAY, INC",35640,PACKARD CHILDREN'S HOSPITAL AT STANFORD,2012,second_quarter,PHA,H.R. 4274 BEST Pharmaceuticals for Children Act and Pediatric Research Equity Act; FDA Safety and Innovation Act,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2012-07-18T11:28:06.237000-04:00
1268854,49f6b68a-f3b0-4fcf-bcd2-04765860f939,Q2,"CARPI & CLAY, INC",35640,STANFORD HEALTH CARE,2012,second_quarter,PHA,"Prescription Drug User Fee Act; legislation related to drug shortages (S. 296, H.R. 2245); FDA Safety and Innovation Act","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2012-07-18T11:36:42.940000-04:00
1269186,e3b06ca2-8a94-4033-8f32-6154a52d3829,Q2,FORGE FEDERAL AFFAIRS LLC,400865535,LILLY USA LLC,2012,second_quarter,PHA,Issues related to Prescription Drug User Fee Act (PDUFA).,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2012-07-18T12:14:56.257000-04:00
1269398,033b1305-e8d0-4e5a-bc49-91f94f2762a3,Q2,COVIDIEN LP,319778,COVIDIEN LP,2012,second_quarter,PHA,Issues involving controlled substance and pain and addiction drugs generally;  H.R. 2119: Ryan Creedon Act of 2011; Issues related to acetaminophen,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,440000,0,0,2012-07-18T12:50:30.033000-04:00
1269787,f5fe231e-e287-464f-bb21-f6d4ed655062,Q2,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2012,second_quarter,PHA,"Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including drug shortage legislation (S. 296, H.R. 2245), potential drug shortage legislation, potential price gouging legislation, medical device pricing issues, and preserving access to group purchasing organizations; The Food and Drug Administration Safety and Innovation Act (S.3187).","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",,220000,0,0,2012-07-18T13:32:58.727000-04:00
1269837,f5efb0c9-41d0-4387-b258-bb8cdb10b6c2,Q2,MICHAEL L. TINER,38175,PHARMACEUTICAL INDUSTRY LABOR-MANAGEMENT ASSOCIATION,2012,second_quarter,PHA,FDA Reauthorization Pharmaceutical Industry Employment Issues,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2012-07-18T13:44:15.670000-04:00
1270044,1d7aef5b-2920-46f1-9f7e-2b1a141e2a69,Q2,EISAI INC.,400321512,EISAI INC.,2012,second_quarter,PHA,"Food and Drug Administration-Drug Enforcement Agency coordination and scheduling issues
drug importation
Prescription Drug User Fee Act reauthorization (HOPE Act, supply chain integrity)","HOUSE OF REPRESENTATIVES,SENATE",,610000,0,0,2012-07-18T14:18:24.803000-04:00
1270160,bd14dc30-8a77-4759-8ca1-7269c892fea7,Q2,OCHSNER CLINIC FOUNDATION,45391,OCHSNER CLINIC FOUNDATION,2012,second_quarter,PHA,"S. 296 A bill to amend the Federal Food, Drug, and Cosmetic Act to provide the Food and Drug Administration with improved capacity to prevent drug shortages.  All Provisions.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,160000,0,0,2012-07-18T14:32:15.980000-04:00
1270264,007b0088-a962-4c26-9c07-dc316e0b4b00,Q2,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2012,second_quarter,PHA,"S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUM S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; S. 3376, PACT Act, Hydrocodone issues","Agency for Healthcare Research & Quality (AHRQ),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Federal Trade Commission (FTC),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE",,340000,0,0,2012-07-18T14:45:56.750000-04:00
1270326,2b8eb2f5-0ed5-49fa-94cc-73176f576b53,Q2,"POWERS PYLES SUTTER & VERVILLE, P.C.",32008,340B HEALTH,2012,second_quarter,PHA,"Section 340B of the Public Health Service Act, Section 1927 of the Social Security Act and issues related to (1) administration of the 340B Drug Discount Program, (2) implementation of 340B-related provisions in the Patient Protection and Affordable Care Act of 2010, (3) funding of the Health Resources and Services Administration (HRSA) under the FY2012 Labor Health & Human Services & Education appropriations bills, and (4) enactment of the 340B Program Improvement Act of 2011 (H.R. 2674).","Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2012-07-18T14:57:26.337000-04:00
1270350,d5ab8734-5d32-4d1b-8dad-fd2bbd21cc1f,Q2,KNIGHT CAPITOL CONSULTANTS,40036301,GENZYME CORPORATION,2012,second_quarter,PHA,"S. 606, Creating Hope Act of 2011, S. 296/H.R. 2245, Preserving Access to Life-Saving Medications Act
Reauthorization of the Prescription Drug User Fee Act (H.R. 5651/S. 3187)
H.R. 4132, Faster Access to Specialized Treatments Act/S. 2113, Transforming the Regulatory Environment to Accelerate Access to
Treatment (TREAT) Act","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-18T15:00:36.317000-04:00
1270814,e46725e6-adf0-4667-8d13-b435770d62e9,Q2,FAEGRE BAKER DANIELS CONSULTING,34158,ALLIANCE FOR SAFE ONLINE PHARMACIES (ASOP),2012,second_quarter,PHA,Online Pharmacies,"Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2012-07-18T15:54:19.760000-04:00
1270975,7c3cf38a-d370-47f4-8f68-f1e028c6785d,Q2,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,31348,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION,2012,second_quarter,PHA,"H.R. 1409:  All provisions of the Quality Health Care Coalition Act of 2011; H.R. 891/S. 274:  All provisions of the Medication Therapy Management Benefits Act of 2011;  H.R. 905 /S. 733:All provisions of the legislation to exclude customary prompt pay discounts from manufacturers to wholesalers from the average sales price for drugs and biologicals under Medicare; H.R. 979 - All provisions of the FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act

H.R. 605 / S. 312 -All provisions of the Patients Freedom to Choose Act 

S. 27 - All provisions of the Preserve Access to Affordable Generics Act 

S. 31 - All provisions of the Prescription Drug and Health Improvement Act of 2011

S. 44 -All provisions of the Medicare Prescription Drug Price Negotiation Act of 2011

H.R. 999 / S. 560 - All provisions of the Medicare Prescription Drug Savings and Choice Act of 2011

H.R. 1839  - All provisions of the Community Pharmacy Fairness Act of 2011;

H.R. 1946 - All provisions of the Preserving or Hometown Independent Pharmacies Act of 2011;

H.R. 1971 / S. 1058 - All provisions of the Pharmacy Competition and Consumer Choice Act of 2011

Provisions of PL 111-148 and PL 111-152 impacting Medicare Part D such as formulary requirements, PBM disclosure provisions, closing the Part D coverage gap

Regulatory design and coverage of pharmacy benefits in health reform exchanges and the commercial market (essential health benefits, grandfathering, value-based insurance design, e-prescribing, PBM disclosure requirements, and medical loss ratio)

Regulatory and proposed legislative changes to Medicare part D including EGWP waivers, MTM expansion, long term care short-term fills, recovery audit contractors

Implementation of changes to the definition of Average Manufacturer Price in Medicaid

Issues related to the management of Medicaid prescription drug benefits

Legislation to promote generic drugs

FDA issues related to the Prescription Drug User Fee Act (PDUFA) (generic user fees, pedigree, REMs); implementation of approval pathway for generic biologic drugs

340b program

H.R. 2672  the Preserving Access to Orphan Drugs Act

H.R. 2182  the Generating Antibiotic Incentives Now Act

H.R. 3026  the Safeguarding Americas Pharmaceuticals Act

H.R. 2746  the Cancer Drug Coverage Parity Act

H.R.4215 - All provisions of the Medicare Pharmacy Transparency and Fair Auditing Act","Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE",,520388,0,0,2012-07-18T16:16:37.717000-04:00
1271073,259f1fc5-d6bc-40ca-823c-368f4658191e,Q2,UPS (UNITED PARCEL SERVICE),39223,UPS (UNITED PARCEL SERVICE),2012,second_quarter,PHA,"-  S. 3187 Food & Drug Administration Safety Innovation Act / HR 5651 Food and Drug Administration Reform Act of 2012
- Healthcare Supply Chain Safety - track and trace in the Prescription Drug Users Fee Act","Commerce, Dept of (DOC),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Internal Revenue Service (IRS),Labor, Dept of (DOL),Postal Regulatory Commission,SENATE,State, Dept of (DOS),Transportation, Dept of (DOT),Transportation Security Administration (TSA),Treasury, Dept of,U.S. Customs & Border Protection,U.S. Postal Service (USPS),U.S. Trade Representative (USTR),White House Office",,1205303,0,0,2012-07-18T16:24:09.123000-04:00
1271862,078151ec-9507-46f4-8952-52fce32945dd,Q2,"GOVBIZ ADVANTAGE, INC.",294234,CATALYST HEALTH SOLUTIONS (CATAMARANRX),2012,second_quarter,PHA,Pharmacy Benefit Issues in health legislation;  PBM issues; General company congressional relations; business issues; oversight of PBMs,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2012-07-18T18:52:40.493000-04:00
1272260,b37f62b3-1b93-4960-b3fb-a8e81fed7567,Q2,VAN SCOYOC ASSOCIATES,39837,UNIVERSITY OF CONNECTICUT,2012,second_quarter,PHA,"Issues related to FDA salaries and expenses; and extramural research:
    S.2375/H.R.5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 
   FY2013
   Public Law 112-55, Consolidated and Further Continuing Appropriations Act, FY2012","Commerce, Dept of (DOC),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2012-07-19T07:00:24.287000-04:00
1272270,d3ef0c59-18b5-4cc6-bfc3-2ee664594ead,Q2,VAN SCOYOC ASSOCIATES,39837,UNIVERSITY OF PENNSYLVANIA SCHOOL OF MEDICINE,2012,second_quarter,PHA,"FDA funding initiatives; Critical Path Partnership.
  S.2375/H.R.5973, Agriculture,Rural Development,Food and Drug Administration,and Related Agencies Appropriations Act, FY2013
  Public Law 112-10, Department of Defense and Full-Year Continuing Appropriations Act, FY2011
  Public Law 112-55, Consolidated and Further Continuing Appropriations Act, FY2012 Monitor Prescription Drug User Fee Act (PDUFA)",SENATE,50000,,0,0,2012-07-19T07:01:26.270000-04:00
1272282,b4cb377c-9efb-48dc-a797-bea0d9fa0e26,Q2,"RUBICON ADVISORS, LLC",315091,"BOEHRINGER INGELHEIM PHARMACEUTICALS, INC.",2012,second_quarter,PHA,"Physician Payment Sunshine Act S 2029
Patent Settlements H.R. 14328 .316
Affordable Healthcare Choices Act","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-19T07:14:30.977000-04:00
1272286,0d76f160-ca11-40a9-8faf-60afc26b9374,Q2,"RUBICON ADVISORS, LLC",315091,GILEAD SCIENCES,2012,second_quarter,PHA,"H.R. 822, H.R. 1943, H.R. 6114, S-2969","HOUSE OF REPRESENTATIVES,SENATE",75000,,0,0,2012-07-19T07:18:33.157000-04:00
1272287,0ad4e1cb-2d80-4a78-b793-9452a84a8cf3,Q2,"RUBICON ADVISORS, LLC",315091,TEVA PHARMACEUTICALS USA,2012,second_quarter,PHA,"Patent Settlements H.R. 1432, Generic Biologies S H.R. 1695, H.R. 5629, Physican Payment Sunshine Act S 2029, Patent Reform H.R. 1908, Import Safety Act H.R. 3100
Affodable Health Choices Act","HOUSE OF REPRESENTATIVES,SENATE",105000,,0,0,2012-07-19T07:22:34.463000-04:00
1272288,f744500b-0315-4411-9efc-7684512ec227,Q2,"RUBICON ADVISORS, LLC",315091,WATSON PHARMACEUTICALS INC,2012,second_quarter,PHA,"Patent Reform H.R. 1908, Import Safety Act H.R. 2100     Affordable Health Choices Act
Patent Settlements H.R. 1432 S 316
Generic Biologics S 1685 H.R. 5629
Physician Payment Sunshine Act S 2029","HOUSE OF REPRESENTATIVES,SENATE",98000,,0,0,2012-07-19T07:25:35.157000-04:00
1272308,c17c2eb4-7d89-4102-a346-edba1bdb981d,Q2,AARP,1694,AARP,2012,second_quarter,PHA,"Discussed legislative intent with respect to Biologic drugs and exclusivity period.(no bill)
Discussed importance of potential savings both to consumers and to the federal government of granting Secretarial Negotiating Authority to Secretary of HHS on Medicare Part D. (no bill) Discussed legislative intent with respect to biologic drugs and the exclusivity period; and discussed importance of potential savings to the health care system generally. (no bill)
Discussed need for greater consumer safety protections both in OTC and prescription drugs. (no bill)
Discussed need to end industry tactics like Pay for Delay which inappropriately extends patents with effect of keeping prices high for consumers and government. (no bill)
Discussed need for doctors to get unbiased information on prescription pharmaceuticals through programs like academic detailing. (no bill)
Discussed possible savings and better health care outcomes that could result from Medication Therapy Management. (no bill)
Pub. Law 111-148 and 111-152 - Discussed implementation of health care legislation to reform the health care system to provide quality healthcare, expand access to long-term services and supports, and reduced prescription drug costs.
Discussed greater affordability of generic versions of both generic and biologic drugs.
S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011 - Discussed legislation that establishes a framework for the safe, legal importation of lower-priced prescription drugs from abroad.
S. 1206, Medicare Drug Savings Act of 2011 - Discussed rebates in Medicare Part D as a cost savings measure in Medicare that does not harm beneficiaries.
H. R. 3342, Affordable Medicines Utilization Act of 2011 - Lobbied on legislation to encourage state Medicaid programs to use safe, effective generic medications.
S. 27, Preserve Access to Affordable Generics Act - Lobbied for this legislation preventing abuses in patent settlements between generic and brand name prescription drug companies.
S. 1886/H.R. 3468, Discussed counterfeit drug penalty enhancement. 
Discussed prescription drug safety, drug shortage, and medical device safety, and related user fee legislation.
S. 2193, the Ensuring Safe Medical Devices for Patients Act - Discussed legislation to include devices in the post-market risk identification and analysis system for prescription drugs and to expedite the implementation of the unique device identification system for medical devices.
Discussed draft legislation to address the issue of whether generic drug manufacturers have a duty to include new warnings about potentially serious side effects on their labels as they become known. The bill would accomplish this by giving generic drug makers the same ability to update their labeling as currently exists for manufacturers of brand name drugs. (no bill)
S.3187, Food and Drug Administration safety and Innovation Act - FDA user fee agreement legislation focusing on the review process for prescription drugs and medical devices, prescription drug safety, drug shortages, medical device safety and access to generic drugs.
S. 1882, Fair and Immediate Release of Generic Drugs Act or the FAIR Generics Act - Discussed pay-for-delay amendment to the FDA user fee agreement legislation based the stand-alone bill.
S.3212, Cody Miller Initiative for Safer Prescriptions Act - To require the Secretary of Health and Human Services to promulgate regulations regarding the authorship, content, format, and dissemination of Patient Medication information.","Administration on Aging,Agriculture, Dept of (USDA),Bureau of the Census,Centers For Medicare and Medicaid Services (CMS),Energy, Dept of,Equal Employment Opportunity Commission (EEOC),Executive Office of the President (EOP),Federal Communications Commission (FCC),Federal Energy Regulatory Commission (FERC),Federal Highway Administration (FHA),Federal Reserve System,Federal Trade Commission (FTC),Federal Transit Administration (FTA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Internal Revenue Service (IRS),Justice, Dept of (DOJ),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),Natl Highway Traffic Safety Administration (NHTSA),Office of Management & Budget (OMB),Office of Personnel Management (OPM),Office of the Comptroller of the Currency (OCC),Securities & Exchange Commission (SEC),SENATE,Social Security Administration (SSA),Transportation, Dept of (DOT),Treasury, Dept of,White House Office",,2740000,0,0,2012-07-19T08:30:57.857000-04:00
1272559,c272b597-d709-4045-83d1-91ffd553308e,Q2,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2012,second_quarter,PHA,"Over-the-Counter (OTC) medicines; Manufacturing and importation of OTC drugs; mandatory recall authority of the FDA; Rx-to-OTC Switch H.R. 1483 - Drug Safety Enhancement Act of 2011.  Amends the federal Food, Drug, and Cosmetic Act (FDCA) to expand drug establishment registration requirements to include foreign drug establishments and other purposes; all sections.

S. 1584 - Drug Safety and Accountability Act of 2011.  Amends the federal Food, Drug, and Cosmetic Act (FDCA) to expand registration requirements for drug manufacturers, wholesalers, distributors, and retailers; grants FDA mandatory recall authority; requires adequate documentation of the pharmaceutical supply chain; all sections.

House and Senate drafts of Prescription Drug User Fee Act (PDUFA).  Reauthorizes the Food and Drug Administration (FDA) to collect user fees from pharmaceutical on over-the-counter drug manufacturers; all sections (H.R. 5651/S. 3187).","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,183564,0,0,2012-07-19T09:46:30.007000-04:00
1272719,1bd671ad-0350-4dec-887a-852b53cfd6ac,Q2,SQUIRE PATTON BOGGS (US) LLP (F.K.A. SQUIRE SANDERS (US) LLP),55223,COVERMYMEDS,2012,second_quarter,PHA,Prescription drug prior authorizations and other insurance coverage determinations,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS)",,,0,0,2012-07-19T10:16:42.227000-04:00
1272763,035a0abd-2a07-474d-ab2a-8ab467e6beab,Q2,VAN SCOYOC ASSOCIATES,39837,UNIVERSITY OF MARYLAND BALTIMORE,2012,second_quarter,PHA,"S.2375/H.R.5973, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, FY2013, FDA initiatives; and Critical Path initiative.
S.3187/H.R.5651, Food and Drug Administration Safety and Innovation Act, FDA initiatives; Critical Path issues.","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2012-07-19T10:22:03.487000-04:00
1273143,af7f0b36-4e81-43bd-818a-2a06cdb749a2,Q2,"AMERICAN FEDERATION OF STATE, COUNTY AND MUNICIPAL EMPLOYEES",2321,AMERICAN FEDERATION OF STATE COUNTY AND MUNICIPAL EMPLOYEES,2012,second_quarter,PHA,S 3187 - Food and Drug User Fee Program,"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),SENATE,Treasury, Dept of,White House Office",,670000,0,0,2012-07-19T11:06:47.007000-04:00
1273358,caa844cd-bc52-48b4-aad7-2d0ac659e9a8,Q2,THE DUBERSTEIN GROUP INC.,12675,AMERICA'S HEALTH INSURANCE PLANS,2012,second_quarter,PHA,"*FEHBP prescription drugs - HR 979, FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act.
*Pay-for-delay settlements - S 27, Preserve Access to Affordable Generics Act.
*Antitrust exemption for independent pharmacies - HR 1946, Preserving Our Hometown Independent Pharmacies Act of 2011. *FDA user fee programs - HR 3988, Generic Drug and Biosimilar User Fee Act of 2012.

*Pay-for-delay settlements - HR 3995, Protecting Consumer Access to Generic Drugs Act of 2012.

*FDA oversight of medical devices - S 2193, Ensuring Safe Medical Devices for Patients.

*Pharmaceutical, medical device issues - HR 5651, Food and Drug Administration Reform Act of 2012; S 2516, Food and Drug Administration Safety and Innovation Act; S 3187, Food and Drug Administration Safety and Innovation Act.

*Standards for on-line pharmacies - S 2002, Online Pharmacy Safety Act.",HOUSE OF REPRESENTATIVES,100000,,0,0,2012-07-19T11:21:11.167000-04:00
1273662,fc77c288-0941-4bf5-94bc-508a3a1f4944,Q2,THE DUBERSTEIN GROUP INC.,12675,PFIZER INC.,2012,second_quarter,PHA,"Drug shortages - Proposed legislation re these issues.
Opiate abuse - HR 1316, Stop Oxy Abuse Act of 2011; HR 2119, Ryan Creedon Act of 2011; HR 866, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2011; HR 1065, Pill Mill Crackdown Act of 2011; S 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; Executive Branch action re this issue.

Pharmaceutical issues, including tracking and tracing medicines, fostering competition between generic and brand-name pharmaceutical manufacturers - HR 5651, Food and Drug Administration Reform Act of 2012; S 3187, Food and Drug Administration Safety and Innovation Act.

Incentives to develop antibiotics - HR 2182, Generating Antibiotic Incentives Now Act of 2011; S 1734, Generating Antibiotic Incentives Now Act of 2011.

Establish criminal penalties for trafficking in counterfeit drugs - HR 3468, Counterfeit Drug Penalty Enhancement Act of 2011; S 1886, Counterfeit Drug Penalty Enhancement Act of 2011.

National Center for Advancing Transformational Sciences at FDA; agreement to review compounds for potential new uses - Executive Branch actions re these issues.

*Follow-on biologics generally.

*Certified Importer Program.

*Drug safety - HR 1483, Drug Safety Enhancement Act of 2011.","HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",100000,,0,0,2012-07-19T11:47:19.007000-04:00
1273663,cf3f9ace-fec4-49b2-935d-f5a88627713e,Q2,"FIERCE, ISAKOWITZ & BLALOCK",44812,"SUCAMPO PHARMACEUTICALS, INC.",2012,second_quarter,PHA,General FDA Issues,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2012-07-19T11:47:27.787000-04:00
1273811,cd6ae624-e494-4d6e-b0a2-ae47d4b98e5c,Q2,NATIONAL PATIENT ADVOCATE FOUNDATION,28311,NATIONAL PATIENT ADVOCATE FOUNDATION,2012,second_quarter,PHA,Prescription Drug user fee - drug shortage and breakthrough therapies,,,117181,0,0,2012-07-19T11:58:42.017000-04:00
1273923,5e429515-2332-4475-a4dc-adfc481ee001,Q2,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2012,second_quarter,PHA,General Pharmacy Issues,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2012-07-19T12:09:22.463000-04:00
1274039,33c95072-6bdc-42d5-bec8-d5c04e861c4b,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,PHRMA,2012,second_quarter,PHA,"**see addendum page Prescription drug importation
     S. 319  Pharmaceutical Market Access and Drug Safety Act of 2011
     H.R. 147 - Prescription Drug Affordability Act

S. 3187 - The Food and Drug Administration Safety and Innovation Act (H.R. 3988, H.R. 4087, H.R. 5334, S. 2236, S. 2289, S. 2516)

***, no specific bill(s), prescription drug importation, import safety, supply chain integrity, Prescription Drug User Fee Act and associated policies","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",70000,,0,0,2012-07-19T12:23:10.987000-04:00
1274143,9b775024-74ed-4fc6-ab2f-d79d42ff6f25,Q2,WINSTON & STRAWN LLP,41682,WOCKHARDT USA LLC,2012,second_quarter,PHA,Generic drug issues - federal preemption of state claims; FTC regulation of settlement agreements,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2012-07-19T12:33:57.497000-04:00
1274202,f0d29d5b-c4d6-4ea5-899c-3965e47aca06,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,HEALTHCARE DISTRIBUTION ALLIANCE (HEALTHCARE DISTRIBUTION MANAGMENT ASSN.),2012,second_quarter,PHA,"**see addendum page Importation of prescription drugs (S.319/H.R. 147)
NASPER reauthorization (H.R. 866)
Pill Mill  Crackdown Act (H.R. 1065/S. 1760/S. 2297)
Drug Abuse (S. 507)
Drug Shortages (S. 296/H.R. 2245/H.R. 3839/S.3187/H.R. 5853/H.R. 5651)
Rx Pedigree (H.R. 3026/S. 3187)
Cargo/Product Theft (S. 1002/H.R. 4223)
Import Safety (S. 1584)
Drug Importation (H.R. 2112 - Agriculture, Transportation Appropriations Bill for 2012)
Prescription Drug Monitoring Program  (H.R. 2254/H.R. 4292/S. 3187)
Counterfeit Drugs (S. 1886/H.R. 3668/S. 3187)
Internet Pharmacey (S. 2002/H.R. 4095)

***, no specific bills: supply chain integrity, prescription drug abuse, internet pharmacy regulation","Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2012-07-19T12:37:13.847000-04:00
1274210,065e458e-b27b-46c9-a853-eaf1ace860b9,Q2,HANCE SCARBOROUGH,17443,INTRATHECAL CUSTODY ACCOUNT SUPPORTERS (INFORMAL COALITION),2012,second_quarter,PHA,Monitored legislation related to physician control and patient access to intrathecal pump applications for patients with chronic pain.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2012-07-19T12:38:18.817000-04:00
1274226,2d55eec3-2ae5-4979-8ced-0a4b43de351f,Q2,AMERICAN PHARMACISTS ASSOCIATION,3071,AMERICAN PHARMACISTS ASSOCIATION,2012,second_quarter,PHA,"HCR(PL 111-152/111-148) concerning Medicare PartD;MTM;DME;transitions of care;pharmacy reibursement; loan forgiveness;agency issues concerning risk evaluation mitigation strategies;PDUFA;prescription drug monitoring program,drug abuse,safe drug supply chain;standardized medication action plans;personalized medication lists;ACOs;pharmacists role in CMS Innovation Center initiatives;standardized pharmacy notice;immunization;HIT; medication disposal;biosmiliars;EHB","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Natl Drug Control Policy (NDCP),SENATE",,,0,0,2012-07-19T12:40:26.670000-04:00
1274271,ab503529-9e72-4ddb-8f80-1b74695a1724,Q2,"TARPLIN, DOWNS & YOUNG, LLC",304736,ASTRAZENECA,2012,second_quarter,PHA,"**see addendum page Prescription drug importation
     S. 319  Pharmaceutical Market Access and Drug Safety Act of 2011
     H.R. 147 - Prescription Drug Affordability Act
     H.R. 2182/S. 1734 - Generating Antibiotics Incentives Now Act

S. 3187 - The Food and Drug Administration Safety and Innovation Act (H.R. 3988, H.R. 4087, H.R. 5334, S. 2236, S. 2289, S. 2516)

***, no specific bill(s), Import Safety, Prescription Drug User Fee Act renewal, drug development policy, drug shortages, supply chain integrity, patent settlements","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2012-07-19T12:46:48.940000-04:00